Faeth Therapeutics, Inc
senseibio.comSensei Biotherapeutics (NASDAQ: SNSE) is a clinical-stage biotherapeutics company that develops oncology drug candidates. The company generates no product revenue and funds operations entirely through capital raises, spending on research and development and general and administrative costs. Research and development expenses were $11.0 million for the year ended December 31, 2025. The company has recorded net operating losses since inception and had not recognized any income tax benefits as of the 10-K filed March 30, 2026. In February 2026, Sensei entered into a merger agreement with Faeth Holdings Therapeutics, Inc. and Faeth Therapeutics, LLC, with the agreement dated February 17, 2026. As of the filing date, Christopher W. Gerry served as President and General Counsel and Principal Executive Officer. The company has been audited by the same auditor since 2016.
Products & Services
The company's former lead product candidate was solnerstotug, a clinical-stage oncology asset. Long-lived asset impairments in 2024 reflected a write-down of equipment and finance right-of-use assets tied to streamlining operations and focusing resources on solnerstotug's clinical development. No product revenue has been generated.
Revenue Model
No product or collaboration revenue disclosed in the filing excerpts. Operations funded through capital markets. The company carries net operating loss carryforwards since inception.
Customers & Markets
No commercial customers or paying end markets disclosed in the filing excerpts. The company operates in oncology drug development targeting cancer patients as the ultimate end beneficiary.
Geographic Exposure
Incorporated and operating in the United States. Data transfer obligations under EU GDPR, UK GDPR, and other international privacy regimes are referenced as applicable compliance considerations.
Financial Snapshot
Loading...
